Basic Information
| LncRNA/CircRNA Name | circPVT1 |
| Synonyms | |
| Region | |
| Ensemble | |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung adenocarcinoma |
| ICD-0-3 | C34 |
| Methods | qPCR, RNA pull-down assay |
| Sample | lung adenocarcinoma tissues and cell line |
| Expression Pattern | up-regulated |
| Function Description | The current study found circPVT1 was highly expressed in LAD, which expression was positively related to N stage and chemotherapy insensitivity (cisplatin and pemetrexed) of LAD patients, and it was an independent prognostic biomarker for LAD patients. |
| Pubmed ID | 31986409 |
| Year | 2020 |
| Title | CircPVT1 contributes to chemotherapy resistance of lung adenocarcinoma through miR-145-5p/ABCC1 axis |
External Links
| Links for circPVT1 | GenBank HGNC NONCODE |
| Links for lung adenocarcinoma | OMIM COSMIC |